





Int. J. Mol. Sci. 2021, 22, x. https://doi.org/10.3390/xxxxx www.mdpi.com/journal/ijms 
Article 1 
Interferon-Inducible Transmembrane Protein 1 (IFITM1) Ex- 2 
pressing Transgenic Chicks Restricts Highly Pathogenic H5N1 3 
Influenza Viruses 4 
 5 
Mohammed A. Rohaim 1,2, Mohammad Q. Al-Natour2,3, Mohammed A Abdelsabour4, Rania F. El Naggar5, Yahia M. 6 
Madbouly4, Kawkab A. Ahmed6, Muhammad Munir2,* 7 
1 Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt. 8 
2 Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancas- 9 
ter, LA1 4YG, United Kingdom. 10 
3 Department of Veterinary Pathology & Public Health, Faculty of Veterinary Medicine, Jordan University 11 
of Science and Technology (JUST), 3030 Irbid, 22110 Jordan. 12 
4 Department of Poultry Viral Vaccines, Veterinary Serum and Vaccine Research Institute (VSVRI), Agri- 13 
culture Research Centre (ARC), Cairo, Egypt. 14 
5 Department of Virology, Faculty of Veterinary Medicine, University of Sadat City, Sadat, 32897, Egypt;  15 
6 Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt. 16 
 17 
* Correspondence: muhammad.munir@lancaster.ac.uk 18 
Abstract: Mammalian cells utilize a wide spectrum of pathways to antagonize the viral replication. 19 
These pathways are typically regulated by antiviral proteins and can be constitutively expressed 20 
but also exacerbated by interferon induction. A myriad of interferon stimulated genes (ISGs) have 21 
been identified in mounting broad-spectrum antiviral responses. Members of the interferon-in- 22 
duced transmembrane (IFITM) family of proteins are unique among these ISGs due to their ability 23 
to prevent the virus entry through the lipid bilayer into the cell. In the current study, we generated 24 
transgenic chickens that constitutively and stably expressed chicken IFITM1 (chIFITM1) using avian 25 
sarcoma-leukosis virus (RCAS)-based gene transfer system. The challenged transgenic chicks with 26 
clinical dose 104 egg infective dose 50 (EID50) of highly pathogenic avian influenza virus (HPAIV) 27 
subtype H5N1 (clade 2.2.1.2) showed 100% protection and significant infection tolerance. Although 28 
challenged transgenic chicks displayed 60% protection against challenge with the sub-lethal dose 29 
(EID50 105), the transgenic chicks showed delayed clinical symptoms, reduced virus shedding, and 30 
reduced histopathologic alterations compared to non-transgenic challenged control chickens. These 31 
finding indicate that the sterile defense against H5N1 HPAIV offered by the stable expression of 32 
chIFITM1 is inadequate; however, the clinical outcome can be substantially ameliorated. In conclu- 33 
sion, chIFITM proteins can inhibit the influenza virus replication that can infect various host species 34 
and could be a crucial barrier against zoonotic infections.  35 
 36 
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1. Introduction 39 
The interferon-inducible transmembrane proteins (IFITMs) are a family of small 40 
transmembrane proteins induced by interferon (IFNs) and mount a profound antiviral 41 
state against multiple viruses [1]. The IFITM proteins restrict the viral infections by block- 42 
ing the viral entry and restrict the fusion of the viral and host membranes, thereby inter- 43 
fering with viral entry and replication [2, 3]. It has been shown that IFTIM1, 2, and 3 are 44 
immune-related genes, critically involved in immune defense against a variety of viruses, 45 
including influenza virus, dengue virus, filoviruses, coronavirus, hepatitis C virus, lyssa- 46 
viruses, and West Nile virus [4- 8].  47 
IFITM genes belong to a wider family known as dispanins with a common trans- 48 
membrane domain configuration [5]. The IFITMs are genetically well characterized in ver- 49 
tebrates, and homologs are also known to be present in bacteria [9] while IFITMs in birds 50 
have been given limited attention. IFITMs proteins contain N- and C-termini, two trans- 51 
membrane domains, and a conserved cytoplasmic domain [10]. IFITM1 has a shorter N- 52 
terminal region and is found on the periphery of cells and early endosomes [5]. Chicken 53 
IFITM (chIFITM) locus is clustered on chromosome 5 and contains five genes, 54 
namely chIFITM1, 2, 3, 5 and 10 [7, 11]. The clustering profiles of gene expression reported 55 
the anti-viral response for IFITM1 and IFITM2 while IFITM3 action might be before fusion 56 
of viral membrane leading to viral entry blockage [7]. Previous studies have shown that 57 
host responses to avian influenza infection have varied significantly from chickens and 58 
ducks [7]. The IFITM1, 2 and 3 are strongly up regulated in response to highly pathogenic 59 
avian influenza virus (HPAIV) infection in ducks, whereas little response was seen in 60 
chickens [7]. In vitro overexpression of chIFITM1 has been shown to increase the resistance 61 
of avian cells to AIV infection [7]. 62 
Highly pathogenic avian influenza viruses (HPAIVs) are causing devastating eco- 63 
nomic and welfare impacts on poultry and has significant human health implications 64 
around the globe with concerns on the emergence of new strains that lead to pandemics 65 
[12]. Understanding the host factors related to the virus’s pathobiology in their natural 66 
hosts may help to develop effective intervention strategies and define the genetic markers 67 
for disease resistance. Genetic analysis has suggested that the host restriction factors play 68 
a major role for influenza virus replication [13]. However, only recently the molecular 69 
functions and mechanisms were unraveled. Interactions between viral proteins and host 70 
factors are generally thought to play a major part in viral fitness and pathogenicity, and 71 
adaptive virus mutations lead to optimum interaction with host factors [14]. 72 
In order to map host restriction factors that determine the zoonotic potential and 73 
pathobiology of influenza viruses, we generated transgenic chickens that express 74 
chIFITM1 using avian sarcoma-leukosis virus (RCAS)-based gene transfer system. The 75 
present study shows that chIFITM1 can inhibit H5N1 HPAIV at the clinical challenge dose 76 
while improving the clinical outcome of a sub-lethal challenge dose, which provides proof 77 
of an inhibition of the spread of zoonotic viruses to humans by virus resistance transgenic 78 
chicken. 79 
2. Results 80 
2.1. Efficient Expression of chIFITM1 Using RCAS Vector System 81 
In order to determine the in vivo antiviral ability of chIFITM1 protein against avian 82 
influenza virus subtype H5N1, we generated transgenic chickens stably expressing 83 
chIFITM1 protein. To achieve this transgenesis, we exploited avian retroviruses (RCAS; 84 
Replication Competent ALV LTR with a Splice acceptor) vector-based expression system 85 
to generate mosaic transgenic chicken [15, 16]. The full length open reading frame of 86 
chIFITM1 was cloned between two unique restriction sites to efficiently express a caped 87 
and poly-adenylated transcript (Figure 1A). Correspondingly, RCASBP(A)-WT was used 88 
as negative control in the transgenesis process. Both RCASBP(A)-chIFITM1 and 89 
RCASBP(A)-WT recombinant viruses were rescued using chicken embryo fibroblasts (DF- 90 
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1) to generate mosaic-transgenic chicken embryos for constitutive expression of chIFITM1. 91 
The virus replication was assessed by immunofluorescence staining for the viral structural 92 
protein (gag) and flag-tagged chIFITM1 by confocal microscopy indicating stable 93 
expression of the protein (Figure 1B). Infectious DF1 cells expressing RCAS-mediated 94 
chIFITM1 were further expanded to obtain the required stock density for transgenic 95 
embryo generation.  96 
  97 
Figure 1. Generation and rescue of recombinant retroviruses expressing chIFITM1. (A) A schema 98 
for the generation of recombinant RCAS virus in which src gene was replaced with chIFITM1. (B) 99 
Retroviruses were rescued in DF-1 cells and stained for retroviral structural gag protein and flag- 100 
tagged fused to the chIFITM1.  101 
 102 
2.2. Generation of Transgenic Chicks Expressing chIFITM1 103 
For generation of mosaic transgenic chickens, 2-day-old embryonated SPF eggs were 104 
inoculated with recombinant RCAS viruses (RCASBP(A)-chIFITM1 or RCASBP(A)-WT) 105 
infected DF1 cells (Figure 2A). The hatched chicks were kept in isolators until challenge 106 
with clinical dose of HPAIV H5N1 at 12 days of age then sub-lethal dose on day 20 of 107 
chick’s age (8 days post first infection) (Figure 2A). In two independently performed 108 
experiments, we confirmed that the chIFITM1 expression did not have any detrimental 109 
effect on the chick embryonic development, and hatchability of RCAS-chIFITM1 110 
transgenic eggs compared to mock groups (Supplmenatry data file 1) (Figure 2B). In 111 
addition,  it was noted that all transgenic RCASBP(A)-chIFITM1 or  RCASBP(A)-WT 112 
chicks had a non significant body weight reduction (Supplmenatry data file 2) then 113 
progressively re-gained their body weight as weights of mock inoculated group (negative 114 
control, inoculated with PBS) on the 10th day post-hatch (Figure 2C). All chicks, regardless 115 
of nature of transgenesis either with RCASBP(A)-chIFITM1 or RCASBP(A)-WT, eat 116 
(Figure 2D; Supplmenatry data file 3)  and drunk (Figure 2E; Supplmenatry data file 4) 117 









Figure 2. Generation of transgenic chickens and impact of chIFITM1 on hatchability and physiolog- 124 
ical parameters of hatched chicks. (A) Schema representing the time of transgenesis and challenge 125 
experiments. Comparison of hatchability percentage (B), body weight (C), feed intake (D) and water 126 
consumption (E) of chIFITM1 expressing transgenic chicken and control chicks (RCASBP(A)-WT 127 
and negative control) post-hatching, pre-challenge and post-challenge. Statistical analyses between 128 
different incoulated groups were provided within Supplmentary Data files 1, 2, 3 and 4. Values 129 
of p < 0.05 were considered statistically significant. 130 
 131 
2.3. Challenge Experiments and In Vivo Efficacy of chIFITM1 against Challenge with Clinical and 132 
Sub-Lethal Doses of HPAIV 133 
` There is a direct correlation between the infectious virus dose and the severity of the 134 
clinical infections. Therefore, the nature of HPAIV H5N1 virus and host genetics 135 
determine the clinical outcome of infection [17, 18]. It was critical to determine the 136 
inoculum titre of HPAIV H5N1 that was able to induce clinical disease in chickens. Based 137 
on our previous study, we used the pre-optimized doses 104 EID50 (called thereafter 138 
clinical) and 105 EID50 (called thereafter sub-lethal) of HPAIV H5N1 strain 139 
A/chicken/Egypt_128s_2012 (clade 2.2.1.2) (accession number: JQ858485.1) [13, 19, 20] as 140 
a challenge virus to demonstrate the antiviral potential of chIFITM1 in transgenic chicks.  141 
Interestingly, the transgenic chicks expressing chIFITM1 when challenged with the 142 
clinical dose (104 EID50) of HPAIV (Figure 3A), they were fully protected from clinical 143 
signs. Moreover, the mock inoculated group (positive control-HPAIV) showed severe 144 
clinical signs starting from the 3rd day post-virus inoculation which were further 145 
exacerbated when chicks exposed to sub-lethal dose of H5N1 HPAIV compared to chicks 146 
in mock transgenic non-challenged (negative control) which remained healthy. 147 
Correspondingly, transgenic chicks expressing IFITM1 were completely protected (100%) 148 
from clinical challenge without any apparent clinical disease (Figure 3A). While, the 149 
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transgenic challenged group with sub-lethal dose of HPAIV showed mild disease signs 150 
with 60% protection (survival) with delayed clinical signs appearance by at least by 4 days 151 
suggesting that the sub-lethal dose of HPAI can override the overexpression of chIFITM1. 152 
Transgenic chicks overexpressing IFITM1 were protected from the clinical challenge and 153 
substantially from the sub-lethal challenge which also manifested by delayed clinical 154 
signs by at least by 7 days. While as expected, 100% HPIAV mock transgenic challenged 155 
chicks (mock inoculated sub-lethal challenge) showed severe clinical signs and were 156 
culled or suddenly died due to infection within five days of challenge. Taken together, 157 
our results showed that the overexpression of chIFITM1 has a substantial impact on the 158 
appearance of the HPAIV infection clinical outcome. Likewise, chIFITM1 can protect 159 
chicks from the clinical doses of influenza viruses; however, it is insufficient to completely 160 
protect chickens against the sub-lethal dose of HPAIV. 161 
To confirm that chIFITM1 was successfully expressed in transgenic chickens, a 162 
chIFITM1-specific quantitative PCR was developed. Owing to expression of codon 163 
optimized chIFITM1 through RCASBP(A) (thus different codon usage), the PCR 164 
distinguished the transgene from endogenously expressed chIFITM1. Using this system, 165 
we found a significantly increased level of chIFITM1 in tracheal RNA obtained from 166 
transgenic chickens RCASBP(A)-chIFITM1 compared to control groups either transgenic 167 
group with RCASBP(A)-WT or non-transgenic chickens (mock treated neg. ctrl) (P ˂  0.0001) 168 
(Figure 3B) indicating the successful expression of chIFITM1. 169 
In addition, we explored whether the increased protection in transgenic chicken with 170 
RCASBP(A)-chIFITM1 was mediated by innate immunity because of the correlation 171 
between chIFITM1-mediated induction of innate immunity [7, 11]. The expression levels 172 
of four innate immune genes were evaluated and were chosen based on their antiviral 173 
expression dynamics. Our results revealed that there were no significant differences in 174 
innate immune gene expression levels between transgenic chickens (RCASBP(A)- 175 
chIFITM1) and non-transgenic (mock treated neg. ctrl) (Supplementary Table S1). These 176 
findings suggest that chIFITM1-mediated protection is not linked to enhanced secondary 177 
innate immune responses, and is specific to chIFITM1's direct antiviral actions. 178 





Figure 3. Survival rates and chIFITM1 expression quantification. (A) Percentage survival rates of RCASBP(A)- 181 
chIFITM1 and RCASBP(A)-WT challenged chicks with clinical and sub-lethal doses of H5N1 HPAIV compared 182 
to mock inoculated chicks (negative and positive control groups). (B) Expression of chIFITM1 in HPAI H5N1 183 
challenged transgenic chickens with RCASBP(A)-chIFITM1 compared to transgenic chickens (RCASBP(A)-WT) 184 
and non-transgenic chicken (mock inoculated neg, ctrl), asterisks indicate significant difference.  185 
 186 
2.4. Virus Shedding Evaluation in Transgenic Chickens Expressing IFITM1 Challenged with 187 
HPAIV H5N1  188 
Cloacal and oropharyngeal swabs were collected from all groups (RCASBP(A)- 189 
chIFITM1, RCASBP(A)-WT and mock treated (Neg. Ctrl)) before challenge and every 190 
alternative day post-clinical and sub-lethal challenges to evaluate if chIFITM1 can mediate 191 
reduction in the virus shedding through oropharyngeal and cloacal routes. Our results 192 
revealed that transgenic chickens expressing chIFITM1 following clinical and sub-lethal 193 
challenge with HPAIV showed significant reduction in virus shedding in both 194 
oropharyngeal (Figure 4A) and cloacal swabs (Figure 4A) and the duration of shedding 195 
period compared to mock transgenic (Pos. Ctrl) (Figure 4A and 4B). These results indicate 196 
that chIFITM1 is a key factor in virus replication that contributes to lower the influenza 197 
viral shedding. 198 





Figure 4. Evaluation of viral shedding from A) oropharyngeal and B) cloacal swabs of RCASBP(A)-chIFITM1 201 
and RCASBP(A)-WT challenged chicks with clinical and sub-lethal doses of H5N1 HPAIV compared to mock 202 
inoculated chicks (negative and positive control groups). Each data point represents the virus titers detected in 203 
oropharyngeal and cloacal swabs on day 0, 3, 5, 7, 10 and 14 DPI. Bars represent the standard deviation means. 204 
* indicate the level of significance at P value<0.05. 205 
 206 
2.5. Virus-Induced Histopathologic Lesions Amelioration for Transgenic Chickens Expressing 207 
IFITM1 208 
Trachea and lung organs were collected from inoculated challenged chicks at clinical 209 
and sub-lethal doses followed by histopathological examination compared with non- 210 
inoculated mock controls (positive and negative control groups) in order to assess the 211 
level of protection offered by a stably-expressing chIFITM1 in face of challenge with H5N1 212 
HAPIV along with the induced histopathological changes. Severe histopathological 213 
alterations were noticed in trachaeal sections from mock transgenic challenged control 214 
chicks (after sub-lethal challenge) including necrosis of lamina epithelialis associated with 215 
mononuclear cells infiltration and edema in lamina propria/submucosa layer (Figure 5A) 216 
while necrosis of some mucous secreting glands and edema in lamina propria in sections 217 
from mock transgenic challenged control chicks (after clinical challenge). On the other 218 
hand, trachea collected from transgenic chicks expressing chIFITM1 and challenged with 219 
HPAIV showed no histopathological changes (clinical challenge) while mild 220 
histopathological alterations as  slight edema in lamina propria and few inflammatory 221 
cells infiltrating lamina propria (sub-lethal challenge) (Figure 5A and Supplementary 222 
Table S2). Meanwhile, lungs of transgenic chicks challenged with either sub-lethal or 223 
clinical challenge showed normal parabronchus with slight congestion of pulmonary 224 
blood vessels (Figure 5B and Supplementary Table S2) while lungs of mock transgenic 225 
chicks challenged with either sub-lethal or clinical challenge showed pneumonia 226 
described by inflammatory exudate occluding the air capillaries. These findings indicate 227 
that the defence offered by the substantial expression of chIFITM1 may contribute to its 228 
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antiviral activity against influenza virus replication [7, 11], which collectively reflect upon 229 
the ameliorated clinical outcome and health improvement.  230 
 231 
 232 
Figure 5. Photomicrographs representive H & E stained sections of trachea (A) and lungs (B) collected from  RCASBP(A)- 233 
chIFITM1 and RCASBP(A)-WT challenged chicks with clinical and sub-lethal doses of H5N1 HPAIV compared to mock 234 
inoculated chicks (negative and positive control groups); showing Edema (ED), focal necrosis (NE), inflammatory cells 235 
infiltration (IF), congestion (CO) (scale bar 25 µm). 236 
 237 
3. Discussion 238 
With the increasing global human population, poultry production is critical for the 239 
economy and food security. Although over the years, poultry production has improved 240 
significantly by selective breeding and better genetics, threats raised by evolving and 241 
emerging pathogens have significantly increased, particularly after intensive poultry 242 
breeding systems have been implemented [13]. Innate immune responses are mainly reg- 243 
ulated by cytokines, chemokines and interferon, which are either induced by direct viral 244 
infection or induced by intrinsic activation against pathogens. Mapping cross-species host 245 
restriction factors that determine the zoonotic potential and pathobiology of influenza vi- 246 
ruses is fundamental to understand the molecular factors that regulate the virus-mediated 247 
innate immune responses and mechanistic observations, varying between avian and 248 
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mammals. Meanwhile, additional investigation and better understanding of the alterna- 249 
tive approaches will provide a framework against avian viral diseases and emergency of 250 
zoonotic infections such as influenza viruses by chicken immune regulation and antiviral 251 
protection [21, 22].  252 
The role of interferon stimulating genes (ISGs) against viruses of medical, zoonotic 253 
and veterinary significance has recently been extensively explored [23]. Many of the 254 
IFITM family members have been identified in chicken, including IFITM1, IFITM2, 255 
IFITM3 and IFITM10 [11] and are differentially expressed upon stimulation by type I and 256 
type II IFNs [2]. The IFITM proteins obstruct the cytoplasmic entry for viruses. The mech- 257 
anistic actions of IFITM proteins are depending on inhibition the virus membrane fusion 258 
because of the decreased membrane fluidity, and hence the curvature in the cell mem- 259 
brane outer leaflets [3]; or disruption the homeostatic cholesterol intracellular by preclud- 260 
ing the interaction of oxysterol-binding protein with the vesicle-membrane-protein asso- 261 
ciated protein A [24]. Chicken IFITM1 and IFITM3 were recently described functionally 262 
[7] although most of these studies were carried out either in cells or in ovo, which high- 263 
lights the ability of chIFITM1 as an important host antiviral limitation factor 264 
The RCAS retrovirus gene transfer method offers a simple, cheaper and less labora- 265 
tory intensive method for the retroviral-mediated transgenic expression [16, 25]. While a 266 
non-significant reduced body weight in transgenic chicks at hatching was observed, 267 
hatched chicks regained the weight swiftly and obtained comparable sizes to non-trans- 268 
genic chicks. In the current study, we have generated mosaic transgenic chicken, which 269 
stably and constitutively expresses the chIFITM1 to further explore the in vivo antiviral 270 
function of IFITM1 against highly pathogenic avian influenza virus subtype H5N1. The 271 
transgenic chickens overexpressing chIFITM1 provided strong evidence of its ability to 272 
fully protect chicken against the dose of H5N1 avian influenza viruses that cause clinical 273 
disease signs in chickens. Because of differing pressures in field environments and poultry 274 
susceptibility to environmental stresses leads to pathological symptoms caused by the in- 275 
fluenza virus, we further examine the impact of chIFITM1 on the pre-determined clinical 276 
and sub-lethal dosages [13]. Our results revealed that chIFITM1 alone is inadequate for 277 
complete morbidity and mortality coverage when the "sub-lethal dosage" (105 EID50) was 278 
applied. However, the clinical outcome was considerably enhanced when "clinical dose 279 
104 EID50" was used in transgenic chickens. Nevertheless, these finding specifically ruled 280 
out the likelihood that "clinical dose" pre-exposition could induce adaptive immune re- 281 
sponse to mask the impact of a "lethal dose". These observations clearly indicate the ability 282 
of innate immunity to protect against HPAIV. It is important to mention the defensive 283 
function of chIFITM1 has been tested against extremely virulent virus; highly pathogenic 284 
IAVs that can trigger deaths of up to 100% in infected poultry flocks. Consequently, it is 285 
likely to be believed that chIFITM1 could have significant impacts on comparatively less 286 
virulent virus, which cause only clinical diseases and low deaths such as H9N2 strains of 287 
influenza viruses. 288 
Overexpression of chIFITM1 has not only alleviated the manifestation of clinical dis- 289 
ease signs in HPAIV infected chickens but also reduced the viruses-induced pathological 290 
lesions and virus shedding. Since RCAS-based retroviral gene transfer system is predom- 291 
inantly effective in organs that are rich in endothelial cells [16, 22, 26], we reasoned the 292 
complete blockage of virus shedding in trachea. This substantially reduced virus shed- 293 
ding correlated with the improved tracheal tissue health, which may highlight the expres- 294 
sion and functional importance of chIFITM1 in mucosal surfaces. Meanwhile, chIFITM1 295 
has not only alleviates the clinical outcome of HPAIV infected chickens with symptoms 296 
of pathological illness, but it also decreases the pathology and viral shedding induced by 297 
viruses. As the RCAS propagation mechanism focused is primarily successful in endothe- 298 
lial cell-rich tissues, that might explain why the lower virus replication and shedding in 299 
transgenic chicken overexpressed chIFITM1 compared to wild type chickens. This de- 300 
creases virus accumulation in tandem with the greater protection of tracheal tissues and 301 
may demonstrate the presence and functional value of chIFITM1 on mucosal surfaces. To 302 
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conclude, the antiviral activities of chIFITM1 against HPAI H5N1 was defined by the use 303 
of the animal transgenic model. These findings indicate the ability of the innate immune 304 
system to impart tolerance to viruses in chicken and provide proof of the capacity to pro- 305 
duce virus-resistance transgenic chicken for food protection and to inhibit the spread of 306 
zoonotic viruses to humans. In addition, gaining more understanding of the genetic fac- 307 
tors that determine the susceptibility of poultry to avian influenza viruses will help to 308 
diminish risks to animal and human health via outbreak preparedness, enhancing food 309 
security, and animal health and welfare. However, understanding these factors will not 310 
only help to understand how influenza viruses evolve but also provide evidence how such 311 
host spectrum contributes to circulation of influenza viruses in chicken and their potential 312 
risk to human.  313 
4. Materials and Methods 314 
4.1. Ethics Statement  315 
All animal studies and procedures were carried out in strict accordance with the 316 
guidelines for Animal Ethics Committees, Department of Poultry Viral Vaccines, Veteri- 317 
nary Serum and Vaccine Research Institute (VSVRI), Agriculture Research Centre (ARC), 318 
Egypt. The study was conducted according to the guidelines of the Declaration of the Vet- 319 
erinary Serum and Vaccine Research Institute (VSVRI) and approved by the Institutional 320 
Review Board (VSVRI-20180206). 321 
 322 
4.2. Cells, Viruses and Antibodies 323 
DF1 cells (chicken fibroblast line; ATCC CRL-12203) were cultured in Dulbecco’s 324 
modified Eagle’s medium (DMEM) (Gibco, Carlsbad, CA) supplemented with 10% inac- 325 
tivated fetal bovine serum (FBS) 120 (Gibco), 2 mM l-glutamine (Gibco) and 100U/mL pen- 326 
icillin/streptomycin (Gibco) at 37°C in 5% CO2. Influenza A virus strain 327 
A/chicken/Egypt_128s_2012 (clade 2.2.1.2) (accession number: JQ858485.1) was propa- 328 
gated in 9 days old specific pathogen free (SPF) chicken eggs and the median egg infec- 329 
tious doses 50 (EID50) were determined in SPF eggs using the Reed and Muench method 330 
[27]. AMV-3C2-S (gag) antibodies were purchased from Hybridoma Bank of Iowa, Uni- 331 
versity of Iowa. The α-flag antibodies for the detection of FLAG tag-fused chIFITM1 were 332 
purchased from Sigma. Alexa-four 568 and 488 secondary antibodies were purchased 333 
from Invitrogen Carlsbad, CA, USA. 334 
 335 
4.3. Construction and Rescue of RCAS Viruses Expressing chIFITM1 336 
The open reading frame of chIFITM1 codon-optimized and chemically synthesised 337 
in-fusion with Flag-tag and sub-cloned to an improved form of RCASBP(A)-∆F1 (kindly 338 
provided by Stephen H. Hughes, National Cancer Institute, MD, USA) using ClaI and 339 
MulI restriction sites. This restriction digestion excised the src gene and replaced it with 340 
chIFITM1 while maintaining the splice accepter signals. This new vector was designated 341 
as RCASBP(A)-chIFITM1. In order to generate reporter RCASBP(A) system, the GFP cod- 342 
ing sequence was cloned between ClaI and MulI and the resulting plasmid was labelled 343 
as RCASBP(A)-eGFP [24]. The sequence integrity and orientation were confirmed by 344 
Sanger’s sequencing. To rescue recombinant RCASBP(A) retroviruses, we followed the 345 
methods previously described [24]. Briefly, DF1 Cells transfected with each of the 346 
RCASBP(A)-eGFP, and RCASBP(A)-chIFITM1 plasmids using Lipofectamine 2000 in Opti 347 
MEM with a pre-determined optimized ratio of 1:3 (Invitrogen, Carlsbad, CA, USA). Me- 348 
dia were changed 6 h post transfection and replaced DMEM supplemented with 5% FCS 349 
and 1% penicillin/streptomycin for 48h. Cells were expanded until the desired number of 350 
cells (106 cells/egg) was achieved.  351 
 352 
4.4. Confocal Microscopy  353 
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Expression of the reporter gene (GFP) was monitored using fluorescence microscopy 354 
(Figure S1) whereas replication efficiencies of chIFITM1 expressing retroviruses were as- 355 
sessed by staining the gag protein of RCASBP(A) and chIFITM1-Flag tag. DF1 cells were 356 
grown on coverslips in 24-well plates, were infected with retroviruses (RCASBP(A)- 357 
chIFITM1) for 48 h. Cells were then fixed for 1 h using 4% paraformaldehyde and perme- 358 
abilised using 0.01% Triton-X100 before incubation with primary antibodies raised against 359 
Flag tag, and or gag protein of retroviruses. Afterwards, cells were incubated with corre- 360 
sponding secondary antibodies for 2 h at room temperature. Cell nuclei were stained with 361 
4′, 6-diamidino-2-phenylindole (DAPI), and the images were taken using a Zeiss confocal 362 
laser-scanning microscope (Zeiss, Kohen, Germany). The confocal images were taken with 363 
40X and 63X high numerical-aperture oil immersion objective lenses on an upright Zeiss 364 
LSM800 confocal microscope. The image size was set 1024×1024 pixels. To eliminate inter- 365 
channel cross talk, multitrack sequential acquisition settings were used. A 568 nm diode- 366 
pumped solid-state laser and an argon ion laser's 488 nm line were used for excitation. 367 
Zeiss Zen control software, which provide numerous viewing features for the observation 368 
and creation of high-quality confocal images, was used to establish optimized emission 369 
detection bandwidths. 370 
 371 
4.5. Generation of Transgenic Chickens and H5N1 HPAIV Challenge 372 
SPF eggs were acquired from a local supplier in co-operation with Department of 373 
Poultry Viral Vaccines, Veterinary Serum and Vaccine Research Institute (VSVRI), Agri- 374 
culture Research Centre (ARC), Egypt. Mosaic-transgenic chicken embryos were gener- 375 
ated by inoculation of 106 RCASBP(A)-chIFITM1 or empty RCASBP(A)-WT infected DF- 376 
1 cells into SPF chicken eggs through the intra-yolk sac using 24G needles at day 2 post- 377 
embryonation (ED2). Embryos were fixed for 2 h post-inoculation before incubation at 378 
37◦C with 60–80% humidity in rotating incubator (twice daily). Transgenic embryos were 379 
allowed to hatch naturally at 21 days of incubation (ED21) (Figure 2A). Each group of 380 
transgenic chickens was housed separately at Containment Level 3 isolators. Food and 381 
water were provided ad libitum, and general animal care was provided by the animal 382 
house staff as required. 383 
The virus dosage optimization (clinical and sub-lethal doses) for HPAIV H5N1 was 384 
carried out in our previously study [13]. A total of 20 RCASBP(A)-chIFITM1, 20 385 
RCASBP(A)-WT transgenic chicks and 15 mock-inoculated chicks (positive control) were 386 
challenged with 104 EID50 H5N1 HPAIV (clinical dose) on 12 days of age post-hatching 387 
(PH12). On the other hand, 10 chicks were kept as a naïve negative control group (non- 388 
inoculated-non challenged, inoculated with PBS). Before second challenge with the sub- 389 
lethal dose (105 EID50 H5N1 HPAIV) on day 20 old post-hatching (PH20), three chicks from 390 
all groups were sacrificed for histopathological examination. All birds in all groups were 391 
monitored for the following 15 days to monitor the appearance of clinical signs, weight 392 
gain (Figure 2C), feed intake (Figure 2D) and water intake (Figure 2E) and mortalities in 393 
all groups. The experiment was terminated at day 35 (PH35) and all remaining chicks 394 
were euthanized. 395 
 396 
4.6. Confirmation of chIFITM1 Expression and Quantitative Assessment of the Chicken Antiviral 397 
Immune Responses 398 
Total RNA was extracted from trachea and lung, which were collected from trans- 399 
genic (RCASBP(A)-chIFITM1) and non-transgenic chickens (mock treated neg. ctrl) using 400 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). A total of 150 ng of RNA was used in the 401 
PCR reactions using SuperScript® III Platinum® SYBR® Green One-Step qRT-PCR Kit 402 
(Invitrogen, Carlsbad, CA, USA) as described earlier [25]. The abundance of specific 403 
chIFITM1 mRNA was compared to the 28S rRNA. The reactions were run using CFX96™ 404 
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Real-Time PCR machine (BioRad, UK) and the data were analyzed using the ddCt method 405 
[28]. 406 
In order to determine the expression of innate immune genes, total RNA was ex- 407 
tracted as described above using TRIzol reagents (Invitrogen, Carlsbad, CA, USA). Invi- 408 
trogen™ SuperScript™ III Platinum™ One-Step qRT-PCR Kit (Invitrogen, Carlsbad, CA, 409 
USA) was used for quantification of the abundances of specific innate immune genes 410 
mRNA in trachea of transgenic chickens with RCASBP(A)-chIFITM1, non-transgenic 411 
(mock treated pos. ctrl) chicks challenged with HPAIV H5N1 and negative control birds 412 
compared to corresponding 28S rRNA (housekeeping gene) and the average fold changes 413 
were determined as provided in Supplementary Table 1. Primers for innate immune genes 414 
are provided in Supplementary Table S2. 415 
 416 
4.6. Virus Shedding and Histopathology 417 
Cloacal and oropharyngeal swabs were collected separately, placed in virus 418 
transport medium, filtered through a 0.2µm filter and then aliquoted and stored at −70 °C 419 
until all samples were collected before analysis using haemagglutination assay as previ- 420 
ously described [29]. Selections of tissues including trachea and lung were collected and 421 
fixed at room temperature for 48 hours by immersion in 10 % neutral buffered formalin 422 
followed by paraffin wax embedding. The 5µm tissue sections were stained using Hae- 423 
matoxylin & Eosin stain before examination under light microscope for any microscopic 424 
lesions. Quantitative scoring for histopathological lesions for the trachea and lungs were 425 
evaluated on a scale from 0 to 3 based on the lesion severity grade (mild, moderate, and 426 
severe) as follow: 0 = no changes, 1 = mild, 2 = moderate, 3 = severe [30]. 427 
 428 
4.7. Statistical Analysis  429 
Pairwise comparisons of challenged (clinical and sub-lethal doses) and control groups 430 
(positive and negative) were performed using Student’s t-test. Kaplan-Meier analysis was 431 
performed to calculate the survival rates. Two-tailed Student’s t test and one-way analysis 432 
of variance (ANOVA) were used to determine differences between groups. Statistical sig- 433 
nificance is shown with values of p< 0.05. All data were represented as the mean ± stand- 434 
ard deviation (SD). Statistical analyses were conducted using GraphPad Prism 7 435 
(GraphPad Software, La Jolla, CA, USA). 436 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1. 437 
Generation and rescue of recombinant retroviruses expressing marker gene (eGFP). Supplementary 438 
data 1 file represents the statistical analysis for hatchability between different inoculated groups. 439 
Supplementary data file 2 represents the statistical analysis for the average body weight between 440 
different inoculated groups during the experiment. Supplementary data file 3 represents the statis- 441 
tical analysis for the average feed intake between different inoculated groups during the experi- 442 
ment. Supplementary data file 4 represents the statistical analysis for the average water consump- 443 
tion between different inoculated groups during the experiment. Supplementary Table S1: 444 
Histopathological lesion scores for tracheas and lungs of different. Supplementary Table S2: Expres- 445 
sion of innate immune genes in transgenic and non-transgenic chicken challenged with HPAI H5N1.  446 
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